Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider.

MedStar author(s):
Citation: Journal of Emergency Medicine. 54(1):73-80, 2018 Jan.PMID: 28987311Institution: MedStar Washington Hospital CenterDepartment: Emergency MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Diabetes Mellitus/dt [Drug Therapy] | *Drug Therapy/td [Trends] | *Emergency Medicine/td [Trends] | Dipeptidyl Peptidase 4/ag [Agonists] | Dipeptidyl Peptidase 4/tu [Therapeutic Use] | Glucagon-Like Peptide-1 Receptor/ai [Antagonists & Inhibitors] | Glucagon-Like Peptide-1 Receptor/tu [Therapeutic Use] | Humans | Insulin Glargine/pd [Pharmacology] | Insulin Glargine/tu [Therapeutic Use] | Insulin, Long-Acting/pd [Pharmacology] | Insulin, Long-Acting/tu [Therapeutic Use] | Islet Amyloid Polypeptide/an [Analysis] | Islet Amyloid Polypeptide/tu [Therapeutic Use] | Sodium-Glucose Transporter 2/ai [Antagonists & Inhibitors] | Sodium-Glucose Transporter 2/tu [Therapeutic Use]Year: 2018Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0736-4679
Name of journal: The Journal of emergency medicineAbstract: BACKGROUND: Diabetes mellitus is a disease that affects millions of Americans, and its prevalence is only anticipated to increase in coming years. It is estimated that diabetes-related visits account for 1% of all emergency department (ED) encounters. In recent years, there have been several new categories of medications approved for the treatment of diabetes, including new insulins, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, an amylin analogue, and sodium-glucose cotransporter-2 inhibitors.CONCLUSIONS: Emergency providers will encounter patients taking these newly approved medications, as well as treat those presenting with adverse effects and overdoses from them. As such, emergency providers must have a basic understanding of these new therapies so that they can optimally care for diabetic patients. Copyright (c) 2017 Elsevier Inc. All rights reserved.DISCUSSION: Many of these new therapies have been incorporated as first- and second-line agents for the management of diabetes. Recently approved diabetes medications often have different mechanisms of action and adverse effect and overdose profiles compared to traditional agents, such as sulfonylureas and metformin.OBJECTIVE OF THE REVIEW: This review presents recently approved agents to treat diabetes, with a focus on basic mechanism, place in therapy, and toxicities the ED provider may encounter.All authors: Mazer-Amirshahi M, Pourmand AOriginally published: Journal of Emergency Medicine. , 2017 Oct 05Fiscal year: FY2018Digital Object Identifier: Date added to catalog: 2017-10-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28987311 Available 28987311

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

BACKGROUND: Diabetes mellitus is a disease that affects millions of Americans, and its prevalence is only anticipated to increase in coming years. It is estimated that diabetes-related visits account for 1% of all emergency department (ED) encounters. In recent years, there have been several new categories of medications approved for the treatment of diabetes, including new insulins, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, an amylin analogue, and sodium-glucose cotransporter-2 inhibitors.

CONCLUSIONS: Emergency providers will encounter patients taking these newly approved medications, as well as treat those presenting with adverse effects and overdoses from them. As such, emergency providers must have a basic understanding of these new therapies so that they can optimally care for diabetic patients. Copyright (c) 2017 Elsevier Inc. All rights reserved.

DISCUSSION: Many of these new therapies have been incorporated as first- and second-line agents for the management of diabetes. Recently approved diabetes medications often have different mechanisms of action and adverse effect and overdose profiles compared to traditional agents, such as sulfonylureas and metformin.

OBJECTIVE OF THE REVIEW: This review presents recently approved agents to treat diabetes, with a focus on basic mechanism, place in therapy, and toxicities the ED provider may encounter.

English

Powered by Koha